The Sirtuin 2 Inhibitor AK-7 Is Neuroprotective in Huntington's Disease Mouse Models

Cell Reports

Volumn 2, Issue 6, 2012, Pages 1492-1497

  Chopra, Vanita ^a   Quinti, Luisa ^a   Kim, Jinho ^b,c   Vollor, Lorraine ^a   Narayanan, K Lakshmi ^a   Edgerly, Christina ^b,c   Cipicchio, Patricia M ^b,c   Lauver, Molly A ^b,c   Choi, Soo Hyuk ^d   Silverman, Richard B ^d   Ferrante, Robert J ^b,c   Hersch, Steven ^a   Kazantsev, Aleksey G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VA Pittsburgh Healthcare System   (United States)

^d Chemistry of Life Processes Institute Center for Molecular Innovation and Drug Discovery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 AZEPANYLSULFONYL) N (3 BROMPHENYL)BENZAMIDE; AK 7; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR; HUNTINGTIN; MUTANT PROTEIN; PLACEBO; SIRTUIN 2; SIRTUIN 2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ATROPHY; CELL PROTECTION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENETIC MODEL; HUNTINGTON CHOREA; IN VIVO STUDY; INVERTEBRATE; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUNTINGTON DISEASE; MALE; MICE; MICE, MUTANT STRAINS; NEUROPROTECTIVE AGENTS; SIRTUIN 2;

INVERTEBRATA;

EID: 84871706585     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.11.001     Document Type: Article

References (25)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
2. Barbaric I., Miller G., Dear T.N. Appearances can be deceiving: phenotypes of knockout mice. Brief. Funct. Genomics Proteomics 2007, 6:91-103.
3. Beirowski B., Gustin J., Armour S.M., Yamamoto H., Viader A., North B.J., Michán S., Baloh R.H., Golden J.P., Schmidt R.E., et al. Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc. Natl. Acad. Sci. USA 2011, 108:E952-E961.
4. Bobrowska A., Donmez G., Weiss A., Guarente L., Bates G. SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS ONE 2012, 7:e34805.
5. Choi S.H., Quinti L., Kazantsev A.G., Silverman R.B. 3-(N-arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2). Bioorg. Med. Chem. Lett. 2012, 22:2789-2793.
6. Chopra V., Fox J.H., Lieberman G., Dorsey K., Matson W., Waldmeier P., Housman D.E., Kazantsev A., Young A.B., Hersch S. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. USA 2007, 104:16685-16689.
7. Donmez G., Guarente L. Aging and disease: connections to sirtuins. Aging Cell 2010, 9:285-290.
8. Hersch S.M., Rosas H.D. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 2008, 5:226-236.
9. Ji S., Doucette J.R., Nazarali A.J. Sirt2 is a novel in vivo downstream target of Nkx2.2 and enhances oligodendroglial cell differentiation. J. Mol. Cell. Biol. 2011, 3:351-359.
10. Jia H., Kast R.J., Steffan J.S., Thomas E.A. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum. Mol. Genet. 2012.
11. Jia H., Pallos J., Jacques V., Lau A., Tang B., Cooper A., Syed A., Purcell J., Chen Y., Sharma S., et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol. Dis. 2012, 46:351-361.
12. Luthi-Carter R., Taylor D.M., Pallos J., Lambert E., Amore A., Parker A., Moffitt H., Smith D.L., Runne H., Gokce O., et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl. Acad. Sci. USA 2010, 107:7927-7932.
13. Maxwell M.M., Tomkinson E.M., Nobles J., Wizeman J.W., Amore A.M., Quinti L., Chopra V., Hersch S.M., Kazantsev A.G. The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum. Mol. Genet. 2011, 20:3986-3996.
14. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 2003, 465:11-26.
15. Moscovitch-Lopatin M., Weiss A., Rosas H.D., Ritch J., Doros G., Kegel K.B., Difiglia M., Kuhn R., Bilbe G., Paganetti P., Hersch S. Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease. PLoS Curr. 2010, 2:RRN1205.
16. Moumné L., Campbell K., Howland D., Ouyang Y., Bates G.P. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. PLoS ONE 2012, 7:e31080.
17. North B.J., Marshall B.L., Borra M.T., Denu J.M., Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 2003, 11:437-444.
18. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., Volk C.B., Maxwell M.M., Rochet J.C., McLean P.J., et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007, 317:516-519.
19. Pallos J., Bodai L., Lukacsovich T., Purcell J.M., Steffan J.S., Thompson L.M., Marsh J.L. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 2008, 17:3767-3775.
20. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., Greve D., Hevelone N., Hersch S.M. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131:1057-1068.
21. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., Ryu H., Hersch S.M., Ferrante R.J. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 2005, 490:354-370.
22. Taylor D.M., Balabadra U., Xiang Z., Woodman B., Meade S., Amore A., Maxwell M.M., Reeves S., Bates G.P., Luthi-Carter R., et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem. Biol. 2011, 6:540-546.
23. Truant R., Atwal R.S., Desmond C., Munsie L., Tran T. Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J. 2008, 275:4252-4262.
24. Vaquero A., Scher M.B., Lee D.H., Sutton A., Cheng H.L., Alt F.W., Serrano L., Sternglanz R., Reinberg D. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 2006, 20:1256-1261.
25. Young A.B. Huntingtin in health and disease. J. Clin. Invest. 2003, 111:299-302.